Bicocca Open Archive

Logo unimib boa
LISSONI, ANDREA ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.893
AS - Asia 4.489
EU - Europa 4.356
SA - Sud America 850
AF - Africa 82
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 9
Totale 20.690
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.636
SG - Singapore 1.557
CN - Cina 1.219
HK - Hong Kong 900
RU - Federazione Russa 771
IT - Italia 766
BR - Brasile 680
SE - Svezia 523
UA - Ucraina 510
DE - Germania 483
IE - Irlanda 473
VN - Vietnam 339
GB - Regno Unito 240
CA - Canada 202
FI - Finlandia 145
AT - Austria 132
KR - Corea 97
FR - Francia 90
IN - India 83
AR - Argentina 78
NL - Olanda 49
BD - Bangladesh 45
DK - Danimarca 45
TR - Turchia 45
MX - Messico 42
ID - Indonesia 40
JP - Giappone 39
ZA - Sudafrica 39
PL - Polonia 35
EC - Ecuador 29
IQ - Iraq 26
ES - Italia 24
BE - Belgio 21
PK - Pakistan 15
IR - Iran 14
CO - Colombia 13
VE - Venezuela 12
MA - Marocco 10
PY - Paraguay 10
UY - Uruguay 10
AE - Emirati Arabi Uniti 9
CL - Cile 9
EU - Europa 9
KE - Kenya 9
SA - Arabia Saudita 9
AU - Australia 8
AL - Albania 7
IL - Israele 7
UZ - Uzbekistan 7
CH - Svizzera 6
LT - Lituania 6
PE - Perù 6
TW - Taiwan 6
EG - Egitto 5
JO - Giordania 5
PH - Filippine 5
RO - Romania 5
SN - Senegal 5
TN - Tunisia 5
CZ - Repubblica Ceca 4
RS - Serbia 4
TH - Thailandia 4
BG - Bulgaria 3
BO - Bolivia 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
LA - Repubblica Popolare Democratica del Laos 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CR - Costa Rica 2
DZ - Algeria 2
GR - Grecia 2
HN - Honduras 2
KZ - Kazakistan 2
MK - Macedonia 2
MY - Malesia 2
NG - Nigeria 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
SC - Seychelles 2
AZ - Azerbaigian 1
CI - Costa d'Avorio 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
KH - Cambogia 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
MN - Mongolia 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
QA - Qatar 1
TT - Trinidad e Tobago 1
Totale 20.690
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.846
Woodbridge 1.187
Singapore 900
Hong Kong 888
Ashburn 785
Fairfield 676
Houston 676
Jacksonville 522
Dublin 440
Chandler 414
Wilmington 401
Dearborn 335
Seattle 300
Frankfurt am Main 285
New York 259
Cambridge 255
Princeton 218
Santa Clara 188
Milan 180
Beijing 166
Los Angeles 144
Dallas 142
Hefei 134
Vienna 119
Nanjing 109
Altamura 106
Lawrence 104
The Dalles 93
Lachine 91
Seoul 86
Shanghai 86
Ho Chi Minh City 84
Chicago 80
Moscow 76
Hanoi 62
São Paulo 60
Boardman 49
Fremont 49
Buffalo 47
Andover 46
San Diego 44
Guangzhou 43
Helsinki 39
Rome 38
Nanchang 37
Ottawa 37
Toronto 35
Hebei 34
London 33
Munich 33
Rio de Janeiro 33
Jiaxing 29
Shenyang 29
Changsha 28
Tianjin 28
Warsaw 27
Jakarta 26
Council Bluffs 25
Tokyo 25
Salt Lake City 23
Huizen 22
Brussels 20
Detroit 19
Falls Church 19
Kunming 19
Nuremberg 19
Brooklyn 18
Norwalk 18
Pune 18
Lissone 17
Johannesburg 16
Montreal 16
Ankara 14
Belo Horizonte 14
Brasília 14
Dong Ket 14
Hangzhou 14
Phoenix 14
Shenzhen 14
Atlanta 13
Bologna 13
Mountain View 13
San Francisco 13
Chennai 12
Düsseldorf 12
Jinan 12
Manchester 12
Quito 12
Boston 11
Columbus 11
Da Nang 11
Mexico City 11
Poplar 11
Zhengzhou 11
Amsterdam 10
Buenos Aires 10
Denver 10
Florence 10
Monza 10
Ribeirão Preto 10
Totale 13.891
Salva come PNG Salva come JPEG
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 544
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery 467
Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms 372
Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (Stumps) revealed similarities and differences with leiomyomas and leiomyosarcomas 352
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production 347
Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential 335
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 310
Clinical outcome of patients with malignant tumors associated with mature cystic teratomas of the ovary: A retrospective multicenter Italian study 309
From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach 293
OC13. 02: Reproducibility of IETA terms in describing endometrial pathology 267
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial 267
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 261
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study 246
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 243
Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial 234
The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis 228
Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: Efficacy on pathological response 223
Synchronous early-stage endometrial and ovarian cancer 222
Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors 220
Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer 220
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection 219
Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival 219
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 212
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 211
Uterine leiomyosarcoma: analysis of treatment failures and survival 209
Pre-operative morphological and colour Doppler features of borderline ovarian tumours 206
Early and short-term complications after US-guided puncture of gynecologic lesions: evaluation after 1,000 consecutive cases 204
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group 202
Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review 200
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 198
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 195
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 192
A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer 192
Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells 190
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma 188
Prospective multicenter study on CA 125 in postmenopausal pelvic masses 188
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 185
Prospective multicenter study on the clinical utility of CA 72.4 in post-menopausal patients with pelvic mass 185
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas 184
Endometrial stromal sarcoma: analysis of treatment failures and survival 183
External validation of diagnostic models to estimate the risk of malignancy in adnexal masses 183
Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help 182
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies 181
Brachytherapy for isolated vaginal recurrences from endometrial carcinoma 181
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy 180
Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma 179
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 178
Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study 178
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 178
Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy 176
Ovarian cancer prediction in adnexal masses using ultrasound based logistic regression models: a temporal and external validation study by the IOTA group 173
Safety of transvaginal fine needle puncture of gynecologic masses: a report after 500 consecutive procedures 173
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 172
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis 172
Ultrasound characteristics of endometrial hyperplasia described using IETA terms 172
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 171
Fertility outcomes in stage I ovarian immature teratomas 170
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 170
Ultrasound in the follow-up of young patients with malignant ovarian tumors after conservative surgery 169
Color Doppler ultrasound in the preoperative assessment of adnexal masses 168
Optimal treatment of early-stage ovarian cancer 167
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer 167
Antiemetic efficacy of granisetron in patients with gynecological malignancies 166
Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses 163
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes 160
Imaging in gynecological disease (7): clinical and ultrasound features of Brenner tumors of the ovary 160
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience 159
Endometriomas: Their ultrasound characteristics 159
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study 159
Primary carcinoma of the fallopian tube. A retrospective analysis of 47 patients 157
Effectiveness of autologous blood transfusion in patients undergoing radical hysterectomy 155
Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994 155
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab 154
Clinically oriented three-step strategy for assessment of adnexal pathology 151
Tumor volume as risk factor for nodal diffusion in endometrial cancer 148
The prognostic relevance of histological type in uterine sarcomas: A cooperation task force (CTF) multivariate analysis of 249 cases 147
Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells 147
Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study 146
Ifosfamide in the treatment of malignant epithelial ovarian tumors 145
Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study 145
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma 144
Brain metastases from endometrial carcinoma 143
A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study 142
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients 142
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice 141
Second-look laparotomy in the management of fallopian tube carcinoma 141
Unilocular adnexal cysts with papillary projections but no other solid components: Is there a diagnostic method that can classify them reliably as benign or malignant before surgery? 141
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 138
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial 136
Alpha-fetoprotein in the management of germ cell tumors of the ovary 134
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas 133
Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: An Italian multicentric retrospective analysis 130
Detection of abnormal intrauterine vascularization by color Doppler imaging: A possible additional aid for the follow up of patients with gestational trophoblastic tumors 128
ΔNp63 expression is associated with poor survival in ovarian cancer 126
Fertility-sparing surgery in uterine leiomyosarcoma 122
Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer 120
Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer 119
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer 117
Comparison of methods for monitoring young women with stage I borderline ovarian tumor after conservative surgery 116
Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses 115
Totale 19.166
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.683
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.683
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.195 0 0 0 0 0 153 192 179 195 208 109 159
2021/20221.185 74 91 81 112 105 94 55 91 56 85 108 233
2022/20231.892 256 577 134 137 182 297 13 90 125 17 31 33
2023/20241.380 38 43 77 73 181 353 264 33 133 39 19 127
2024/20253.730 195 512 192 196 303 144 268 125 329 517 318 631
2025/20264.381 860 594 763 891 1.016 257 0 0 0 0 0 0
Totale 21.091